[NFS-02-3] Development of disease-modifying therapy for polyglutamine-linked SCA
Spinocerebellar ataxia (SCA) is neurodegenerative diseases affecting mainly cerebellum and brainstem, and new subtypes and pathologies of SCAs have been continuously discovered in the world. Especially, SCA31 and SCA36 (nicknamed Asidan) were first found in Japanese, and their clinical and pathological features are quite unique compared with other SCAs. Recent discovery of repeat associated non-ATG (RAN) translation in the pathogenesis of hereditary SCAs carrying repeat expansion mutations has tremendously extended our understanding in the pathogenesis of SCA and other neurodegenerative diseases. Furthermore, the development of new therapy for SCAs have been extensively investigated in Japan and the world. The aim of this symposium is to learn and discuss the current clinical, pathological and therapeutic findings of SCAs for Japanese and Asian neurologists and neuroscientists.
2016-presentProfessor, Dept of Neurotherapeutics, Osaka University Graduate School of Medicine
2008-2016 Section Chief, Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry
2007-2008Associate Professor, Div of Clinical Genetics, Dept of Medical Genetics, Osaka University Graduate School of Medicine
2001-2007Assistant Professor, same as the above
2000-2001JSPS Postdoctoral fellow, Dept of Molecular Medical Science, Osaka Bioscience Institute
1997-2000Research Associate, Div of Neurology, Dept of Medicine, Duke University Medical Center, USA
1995Ph.D. (Dr. of Medical Science), Osaka University Graduate School of Medicine
1991-1995Ph.D. student, Osaka University Graduate School of Medicine
1990M.D., Osaka University Medical School
Awards
2016The Award from Japan Society for Dementia Research
2003The Award for Young Investigator of Japanese Society for Neurochemistry
Abstract password authentication.
Password is written on a pocket program and name badge.